DOCSLIB.ORG

Red Blood Cell Transfusion a Pocket Guide for the Clinician

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Red Blood Cell Transfusion a Pocket Guide for the Clinician Red Blood Cell Transfusion A Pocket Guide for the Clinician Robert Weinstein, MD University of Massachusetts Medical School November 2016 Adapted from Red Blood Cell Transfusion: A clinical practice guideline from the AABB, Clinical Practice Guidelines from the AABB: Red blood cell transfusion thresholds and storage, and additional sources Red Blood Cells as a Therapeutic Product Irradiation Prevention of TA-GVHD in certain Radiation dose: 2500 circumstances cGy to center of product Appropriate uses of red blood cell (RBC) transfusion Donor categories Gamma or • Treatment of symptomatic anemia Product donated by family member X-irradiation • Prophylaxis in life-threatening anemia Product from HLA-selected donor Shelf life of irradiated Products from directed donors • Restoration of oxygen-carrying capacity in case of hemorrhage product: up to 28 whose relationship to recipient’s • RBCs are also indicated for exchange transfusion days unless original family has not been established w Sickle cell disease expiration date is w Severe parasitic infection (malaria, babesiosis) Pediatric practice sooner w Severe methemoglobinemia Intrauterine transfusion (IUT) NB: Supernatant K+ w Severe hyperbilirubinemia of newborn Exchange or simple transfusion in may be higher than neonates if prior IUT usual RBC transfusion is not routinely indicated for pharmacologically treatable Congenital immune deficiency Allogeneic HPC states anemia such as: transplant recipient: • Iron deficiency anemia Acute leukemia: HLA-matched or Start with initiation of • Vitamin B12 or folate deficiency anemia family-donated products conditioning regimen Continue throughout Dosage and administration Allogeneic hemopoietic progenitor cell period of GVHD • One unit of RBC will raise the hemoglobin of an average-size adult (HPC) transplant recipient prophylaxis by ~1 g/dL (or raise HCT ~3%) Allogeneic HPC donor 7 days prior to, Usually for at least • ABO group of RBC products must be compatible with ABO group of or during, HPC harvest 6 months recipient Until lymphocytes Autologous HPC recipient 9 • RBC product must be serologically compatible with the recipient are > 1 x 10 /L (see Pretransfusion Testing). Exceptions can be made in Hodgkin disease Indefinitely if treated for chronic emergencies (see Emergency Release of Blood Products). History of treatment with purine GVHD • Rate of transfusion analogues and related drugs w Transfuse slowly for first 15 minutes Fludarabine Autologous HPC recipient w Complete transfusion within 4 hours (per FDA) 2CDA (Cladribine®) Deoxycoformycin (Pentostatin®) 7 days prior to, and Clofarabine (Clolar®) during, harvest Major Red Cell Products for Transfusion Bendamustine (Treanda®) Initiation of Nelarabine (Arranon®) conditioning Most RBC products are derived by collection of 450-500 (±10%) mL of whole blood through 3 months from volunteer donors and removal of the plasma by centrifugation (see History of treatment with post transplant (6 Table 1). After removal of the plasma, the resulting product is red blood cells alemtuzumab (anti-CD52) months if TBI was (referred to informally as “packed red blood cells”). Aplastic anemia on rabbit anti- used) thymocyte globulin The most commonly available US RBC product has a 42-day blood bank shelf life and HCT 55-65%. Pretransfusion Testing Table 1. Special Processing of RBC for Transfusion Prevents incompatible red cell transfusion Process Indications Technical • Compatibility of donor red cells and recipient plasma Considerations • Avoid immune hemolytic transfusion reactions in the recipient Leukocyte Decrease risk of recurrent febrile, Most commonly Reduction nonhemolytic transfusion reactions achieved by filtration Pretransfusion blood sample from the intended recipient Decrease risk of cytomegalovirus Usually soon • Usually EDTA tube (plasma and red cells) (CMV) transmission (marrow after collection • Proper labeling of the sample transplant) (prestorage) w 2 independent patient identifiers Decrease risk of HLA-alloimmunization May be performed w Identity of the phlebotomist Does not prevent transfusion- at bedside w Date and time of sample collection associated graft-versus-host disease <5x106 leukocytes per w Sample rejected without these (TA-GVHD) product (per FDA) • Age of the sample Washing Decrease risk of anaphylaxis in Wash fluid is 0.9% w Up to 3 days if hospital inpatient or, in past 3 months, recipient (removes IgA-deficient patient with anti-IgA NaCl ± dextrose - Has been pregnant residual antibodies Shelf life of washed - Has been transfused plasma) Decrease reactions in patients with RBCs - Has uncertain history of either history of recurrent, severe allergic 24 hours at 1-6°C or anaphylactoid reactions to blood 4 hours at 20-24°C w Longer (often 1–2 weeks, according to hospital policy) for product transfusion May lose 20% of outpatient red cells in washing pre-op testing if negative history within 3 months process Table 2. Pretransfusion Testing • Blood bank unable to determine presence or absence of underlying alloantibodies Test Purpose Reagents Time • All RBC units are crossmatch-incompatible ABO Group & Determine if recipient’s Test recipient’s red ~25 min Rh Type blood group Rho(D) is cells with anti-A, anti-B, Balance of risks positive or negative anti-D; test recipient’s • Severe anemia requiring transfusion support * plasma with A1 and • Possibility of hemolytic transfusion reaction due to undiagnosed B cells underlying alloantibodies Antibody Detect unexpected, Test recipient’s plasma ~50 min Principles of approach to this situation Screen clinically significant with phenotyped • Communication between bedside clinician and transfusion service (non-ABO) anti-RBC “reagent” RBCs physician is essential antibodies in recipient’s plasma w Obtain careful history of prior transfusion or pregnancy - If history negative, probably safe to transfuse ABO-compatible Antibody Identify specificity of Test recipient’s plasma Varies: RBCs Identification anti-RBC antibody if with many “reagent” Hours - If history positive or uncertain, assess risk:benefit of delaying antibody screen is pos RBCs to days transfusion to complete testing Immediate Ensure ABO Test recipient’s plasma ~10 min w Assess how long it may take for blood bank or reference lab to Spin compatibility between with sample of red cells complete pretransfusion testing Crossmatch recipient’s plasma and from product chosen w Agree on best approach to choosing among incompatible RBC (when antibody RBC product chosen for transfusion units (transfusion physician will advise) screen is for transfusion negative) • Attempt to mitigate need for immediate transfusion: bed rest, oxygen Full Serological Ensure full serological Test recipient’s plasma Up to Crossmatch compatibility between with sample of red an hour Ultimately, do not deprive a patient with autoimmune hemolytic anemia (when antibody recipient’s plasma and cells from product of a needed, lifesaving transfusion screen is RBC product chosen chosen for transfusion. • Autoantibody will shorten survival of transfused RBCs and patient’s positive) for transfusion Includes extra endogenous RBCs to a similar extent incubations (e.g. at • Most undetected alloantibodies will cause delayed hemolytic 37°C and with Coombs reagent). transfusion reactions w May be misdiagnosed as worsening of autoimmune hemolysis Electronic Match ABO/Rh Validated blood bank ~10-15 w Not usually life-threatening Crossmatch compatible RBC from computer system. min • Bedside team must be hypervigilant for acute intravascular inventory with patient (not universally whose ABO/Rh status hemolytic reaction during transfusion (see Adverse Effects of available) has been confirmed Transfusion) and who has no history of, and negative testing Red Blood Cell Transfusion for, RBC alloantibodies Table 3. RBC Transfusion Recommendations* for Hospitalized, Hemodynamically Stable Patients in Specific Clinical Situations *A1 is the most common subgroup of Group A Clinical Potential Transfusion Strength of Quality of Emergency Release of Blood Products Situation Threshold Recom- Supporting mendation Evidence An emergency release of blood products is warranted when the clinical setting precludes waiting for completion of pretransfusion and Adult Inpatients, Hgb** ≤ 7 gm/dL Strong Moderate compatibility testing. Examples include: Hemodynamically Stable • Severe, ongoing life-threatening hemorrhage • Life-threatening anemia ICU Patients, Hgb ≤ 7 gm/dL Strong High What you should do: Hemodynamically Stable (adult or • Notify blood bank of need for emergency release of RBCs pediatric) • Complete hospital’s “emergency release” form w Documents your declaration of a transfusion emergency Postoperative Hgb ≤ 8 gm/dL§ Strong Moderate w U.S. federal regulations require 2 specific items on the form Orthopedic or or for symptoms† Cardiac Surgery - Statement of the nature of the emergency (e.g. “massive GI Patients hemorrhage”) - Signature of MD or “equivalent”; (PA, NP, RN, etc. cannot sign) Cardiovascular Hgb ≤ 8 gm/dL‡ Strong Moderate • Send patient blood sample to blood bank ASAP (before emergency Disease or for symptoms† transfusion begins, if possible) Acute Coronary AABB does not Uncertain Very Low Syndrome recommend for or against What you’ll get from the blood bank (depending on how much testing has a liberal or restrictive RBC already been performed): transfusion strategy • Uncrossmatched RBCs (ABO group-specific if determined on a current blood specimen) All Patients Guided by symptoms as Weak Low • Group O RBCs
Load more

Recommended publications
  • Requirements for Blood and Blood Components Intended for Transfusion Or for Further Manufacturing Use
    Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use Office of Blood Research and Review CBER, FDA Ask the FDA Session – AABB Annual Meeting October 26, 2015 1 Outline • Overview – Historical Background – Intent of the Rule – Organization of the Rule • Selected Provisions – Relevant Transfusion-Transmitted Infection – Control of Bacterial Contamination of Platelets – Medical Supervision – Donor Acknowledgement – Alternative Procedures – Donor Eligibility • Implementation 2 GAO Oversight and FDA Concerns • Publish in the form of regulations the guidelines that FDA deems essential to ensure the safety of the blood supply • Concern about the delay in requiring testing for emerging infectious agents, e.g. HTLV • Concern about blood safety and the regulations being out-of-date • Concerns about donor safety 3 Intent of the Final Rule • To better assure the safety of the blood supply and to help protect donor health • To make donor eligibility and testing requirements more consistent with current practices and to provide flexibility with regard to emerging infectious diseases • To accommodate technological advances • To establish requirements for donor education, donor history, and donor testing 4 Organization of the Final Rule - 1 • A. General • B. Definitions (§§ 606.3, 610.39, 630.3, 640.125) • C. Standard Operating Procedures (§ 606.100) • D. Control of Bacterial Contamination of Platelets (§ 606.145) • E. Records (§ 606.160) • F. Test Requirements (§§ 610.40, 640.5, 640.71(a)) • G. Donor Deferral (§ 610.41) 5 Organization of the Final Rule - 2 • H. Purpose and Scope (§ 630.1) • I. Medical Supervision (§ 630.5) • J. General Donor Eligibility Requirements(§ 630.10) • K. Donor Eligibility Requirements Specific to Whole Blood, Red Blood Cells and Plasma Collected by Apheresis (§ 630.15) • L.
    [Show full text]
  • 27. Clinical Indications for Cryoprecipitate And
    27. CLINICAL INDICATIONS FOR CRYOPRECIPITATE AND FIBRINOGEN CONCENTRATE Cryoprecipitate is indicated in the treatment of fibrinogen deficiency or dysfibrinogenaemia.1 Fibrinogen concentrate is licenced for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenaemia and hypofibrinogenaemia,2 and is currently funded under the National Blood Agreement. Key messages y Fibrinogen is an essential component of the coagulation system, due to its role in initial platelet aggregation and formation of a stable fibrin clot.3 y The decision to transfuse cryoprecipitate or fibrinogen concentrate to an individual patient should take into account the relative risks and benefits.3 y The routine use of cryoprecipitate or fibrinogen concentrate is not advised in medical or critically ill patients.2,4 y Cryoprecipitate or fibrinogen concentrate may be indicated in critical bleeding if fibrinogen levels are not maintained using FFP. In the setting of major obstetric haemorrhage, early administration of cryoprecipitate or fibrinogen concentrate may be necessary.3 Clinical implications y The routine use of cryoprecipitate or fibrinogen concentrate in medical or critically ill patients with coagulopathy is not advised. The underlying causes of coagulopathy should be identified; where transfusion is considered necessary, the risks and benefits should be considered for each patient. Specialist opinion is advised for the management of disseminated intravascular coagulopathy (MED-PP18, CC-PP7).2,4 y Cryoprecipitate or fibrinogen concentrate may be indicated in critical bleeding if fibrinogen levels are not maintained using FFP. In patients with critical bleeding requiring massive transfusion, suggested doses of blood components is 3-4g (CBMT-PP10)3 in adults or as per the local Massive Transfusion Protocol.
    [Show full text]
  • Transfusion Service Introduction Blood/Blood Products Requests and Turnaround Time Expectations
    Transfusion Service Introduction All blood products and blood components are supplied to UnityPoint Health-Meriter Hospital by the American Red Cross Blood Services. Pathology consultation is available regarding blood and/or components and dosages. ABO and Rho(D)—specific type is used whenever possible for leuko-poor packed cell transfusions. ABO-compatible blood is used for all plasma and platelet components whenever possible. For any orders involving HLA-matched components, the patient must have been HLA typed (sent to the American Red Cross) a minimum of 48 hours prior to intended infusion of the component. HLA typing is only required once. Blood components that are thawed, pooled, washed, volume-reduced, or deglycerolized for a patient will be charged to the patient even if not transfused. The charge is done because these components may not be suitable for another patient. Examples include: Autologous or directed donations Pooled cryoprecipitate 4-hour expiration Thawed fresh frozen plasma 24-hour expiration Thawed cryoprecipitate 6-hour expiration Deglycerolized red cells 24-hour expiration Washed red cells 24-hour expiration All blood components must be completely infused within 4 hours of release from UnityPoint Health-Meriter Laboratories Blood Bank, or be infused within the expiration time. Refer to UnityPoint Health -Meriter’s Blood and Blood Products Transfusion Policy #123 for additional information located on MyMeriter. Blood/Blood Products Requests and Turnaround Time Expectations Requests from UnityPoint Health-Meriter Hospital are entered in the hospital computer system and print in the UnityPoint Health- Meriter Laboratories Blood Bank. For the comfort of the patient, it is important to coordinate collection for other tests with Blood Bank specimens.
    [Show full text]
  • Blood Product Replacement: Obstetric Hemorrhage
    CMQCC OBSTETRIC HEMORRHAGE TOOLKIT Version 2.0 3/24/15 BLOOD PRODUCT REPLACEMENT: OBSTETRIC HEMORRHAGE Richard Lee, MD, Los Angeles County and University of Southern California Medical Center Laurence Shields, MD, Marian Regional Medical Center/Dignity Health Holli Mason, MD, Cedars-Sinai Medical Center Mark Rollins, MD, PhD, University of California, San Francisco Jed Gorlin, MD, Innovative Blood Resources/Memorial Blood Center, St. Paul, Minnesota Maurice Druzin, MD, Lucile Packard Children’s Hospital Stanford University Jennifer McNulty, MD, Long Beach Memorial Medical Center EXECUTIVE SUMMARY • Outcomes are improved with early and aggressive intervention. • Both emergency blood release and massive transfusion protocols should be in place. • In the setting of significant obstetric hemorrhage, resuscitation transfusion should be based on vital signs and blood loss and should not be delayed by waiting for laboratory results. • Calcium replacement will often be necessary with massive transfusion due to the citrate used for anticoagulation in blood products. • During massive transfusion resuscitation, the patient’s arterial blood gas, electrolytes, and core temperature should be monitored to guide clinical management and all transfused fluids should be warmed; direct warming of the patient should be initiated as needed to maintain euthermia and to avoid added coagulopathy. BACKGROUND AND LITERATURE REVIEW After the first several units of packed red blood cells (PRBCs) and in the face of continuing or worsening hemorrhage, aggressive transfusion therapy becomes critical. This report covers the experience with massive transfusion protocols. Lessons from military trauma units as well as civilian experience with motor vehicle accidents and massive obstetric hemorrhage have identified new principles such as earlier use of plasma (FFP/thawed plasma/plasma frozen within 24 hours/liquid plasma) and resuscitation transfusion while laboratory results are pending.
    [Show full text]
  • Fresh Frozen Plasma in General Practice
    Practical guide to using frozen and fresh frozen plasma in general practice Why every practice should keep a bag in the freezer Kit Sturgess; MA; VetMB; PhD; CertVR; DSAM; CertVC; FRCVS RCVS Recognised Specialist in Small Animal Medicine Advanced Practitioner in Veterinary Cardiology Introduction Keeping stock at reasonable levels in a practice is vital to good business management balancing the need to have a product available against the costs of keeping stock that is not used and potentially may go out of date and need to be replaced (as well as subtle small costs of space, stock taking, disposal of out-of-date product etc.). Practices need, therefore, to make decisions about preparedness for ‘what if’ scenarios and have protocols in place. The difficult question for many practices is how bizarre/uncommon should these scenarios be to warrant keeping a drug or treatment in stock or buying a specialist piece of equipment. This can only really be answered on an individual practice basis as it will depend on the type of cases seen as well as the likely ability of clients to want to pay if the treatment/investigation is expensive and the relationship with other local practices in terms of borrowing treatments or using equipment. It is also important to try and understand the value that a particular drug or treatment will have on morbidity and mortality of a particular condition and whether the patient could be referred onwards if necessary so not having calcium available if presented with a seizuring hypocalcaemic patient would be a significant issue in that patient’s care.
    [Show full text]
  • Blood Banking/Transfusion Medicine Fellowship Program
    DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE BLOOD BANKING/TRANSFUSION MEDICINE FELLOWSHIP PROGRAM THIS NEW ONE-YEAR ACGME-ACCREDITED FELLOWSHIP IN BLOOD BANKING/TRANSFUSION MEDICINE OFFERS STATE OF THE ART COMPREHENSIVE TRAINING IN BLOOD BANKING, COAGULATION, APHERESIS, AND HEMOTHERAPY AT THE MEMORIAL HERMANN HOSPITAL (MHH)-TEXAS MEDICAL CENTER (TMC) FOR PEDIATRICS AND ADULTS. This clinically-oriented fellowship is ideal for the candidate looking for exceptional experience in hemotherapy decision-making and coagulation consultation. We have a full spectrum of medical and surgical specialties, including a level 1 trauma center, as well as a busy solid organ transplant service (renal, liver, pancreas, cardiac, and lung). Fellows will rotate through: Our unique hemotherapy service: This innovative clinical consultative service for the Heart and Vascular Institute (HVI) allows fellows to serve as interventional blood banking consultants at the bed side as part of a multidisciplinary care team; our patients have complex bleeding and coagulopathy issues. Therapeutic apheresis service: This consultative service provide 24/7 direct patient care covering therapeutic plasmapheresis, red blood cell (RBC) exchanges, photopheresis, plateletpheresis, leukoreduction, therapeutic phlebotomies, and other related procedures on an inpatient and outpatient basis. We performed approximately over 1000 therapeutic plasma exchanges and RBC exchanges every year. Bloodbank: The MHH-TMC reference lab is one of the largest in Southeast Texas. This rotation provides extensive experience in interpreting antibody panel reports, working up transfusion reactions, investigating blood compatibility/incompatibility issues, and monitoring component usage. Gulf Coast Regional Blood Center: This rotation provides donor exposure in one of the largest community blood donation centers in the US as well as cellular therapy and immunohematology training.
    [Show full text]
  • Patient's Guide to Blood Transfusions
    Health Information For Patients and the Community A Patient’s Guide to Blood Transfusions Your doctor may order a blood transfusion as part of your therapy. This brochure will focus on frequently asked questions about blood products, transfusions, and the risks and benefits of the blood transfusion. PLEASE NOTE: This information is not intended to replace the medical advice of your doctor or health care provider and is intended for educational purposes only. Individual circumstances will affect your individual risks and benefits. Please discuss any questions or concerns with your doctor. What is a blood transfusion? A blood transfusion is donated blood given to patients with abnormal blood levels. The patient may have abnormal blood levels due to blood loss from trauma or surgery, or as a result of certain medical problems. The transfusion is done with one or more of the following parts of blood: red blood cells, platelets, plasma, or cryoprecipitate. What are the potential benefits of a blood transfusion? If your body does not have enough of one of the components of blood, you may develop serious life-threatening complications. • Red blood cells carry oxygen through your body to your heart and brain. Adequate oxygen is very important to maintain life. • Platelets and cryoprecipitate help to prevent or control bleeding. • Plasma replaces blood volume and also may help to prevent or control bleeding. How safe are blood transfusions? Blood donors are asked many questions about their health, behavior, and travel history in order to ensure that the blood supply is as safe as it can be. Only people who pass the survey are allowed to donate.
    [Show full text]
  • Changes to the Technical Manual, 18Th Edition Monday, November 17, 2014 12:00 P.M
    Changes to the Technical Manual, 18th Edition Monday, November 17, 2014 12:00 p.m. – 1:30 p.m. (ET) / 5:00p.m. – 6:30 p.m. (GMT) When this file is opened, Acrobat Reader will, by default, display the slides including the Acrobat reader controls. To return to full screen mode, hit Ctrl-L on your computer keyboard or use your mouse to click View>Full Screen on the menu bar of the Acrobat Reader program. To take the slides out of full screen mode and display the Acrobat Reader controls, simply hit the Esc key on your computer keyboard. To advance slides during the program, use the Enter, Page Down, down arrow or right arrow on your computer keyboard. To back up slides during the program, use the Page Up, up arrow of left arrow on your computer keyboard. Please remember to logon to the Live Learning Center using your email address and password to complete an evaluation of the program and speakers. At this time, advance to the next slide and wait for the audioconference to begin. A 2014 Audioconference presented to you by AABB The AABB Technical Manual 18th Edition What’s new? www.aabb.org Technical Manual by the Numbers • 1953 =year of first edition • 69 = number of authors/editors this edition • 370,378 = word count • 96 = number of methods • 60 = number of countries where TM is used www.aabb.org It’s a Process www.aabb.org Overview of Changes Major • Molecular testing • Patient blood management • Cellular therapy • Methods Minor • Throughout www.aabb.org 1: Quality Systems 2: Facilities and Safety • These 2 chapters are comprehensive discussions
    [Show full text]
  • Transfusion Medicine/Blood Banking
    Transfusion Medicine/Blood Banking REQUIRED rotation This is a onetime rotation and is not planned by PGY level. Objective: The objective of this rotation is to teach fellows the clinical and laboratory aspects of Transfusion Medicine and Blood Banking as it impacts hematology/oncology. Goals: The goal of this rotation is to teach fellows blood ordering practices, the difference of type and screen and type and cross matches and selection of appropriate products for transfusion. Fellows will also learn to perform, watch type and screen red cell antibodies and will learn the significance of ABO, Rh and other blood group antigen systems briefly so as to understand the significance of red cell antibodies in transfusion practices. Fellows will learn the different types of Blood components, their indications and contraindications and component modification. e.g. Irradiated and washed products, and special product request and transfusions e.g. granulocyte transfusion, CMV negative products etc. Fellows will learn and become proficient in the laboratory aspects of autoimmune hemolytic anemia, coagulopathies and bleeding disorders in relation to massive transfusions and the laboratory aspects and management of platelet refractoriness. Fellows will learn some aspects of coagulation factor replacement for factor deficiencies and inhibitors. Activities: Fellows will rotate in the Blood Bank at UMC and learn to perform, observe and interpret standard blood bank procedures such as ABO Rh typing, Antibody Screen, Antibody Identification and Direct Antiglobulin Test (DAT). Fellows will also watch platelet cross matching for platelet refractoriness. Fellows will attend and present a few didactic lectures of about 40 minutes on Blood Bank related topics as they apply to hematology/oncology like blood group antigens, Blood Component therapy, Transfusion reactions, Autoimmune hemolytic anemia, Platelet immunology and HLA as it applies to transfusion medicine.
    [Show full text]
  • Blood Product Modifications: Leukofiltration, Irradiation and Washing
    Blood Product Modifications: Leukofiltration, Irradiation and Washing 1. Leukocyte Reduction Definitions and Standards: o Process also known as leukoreduction, or leukofiltration o Applicable AABB Standards, 25th ed. Leukocyte-reduced RBCs At least 85% of original RBCs < 5 x 106 WBCs in 95% of units tested . Leukocyte-reduced Platelet Concentrates: At least 5.5 x 1010 platelets in 75% of units tested < 8.3 x 105 WBCs in 95% of units tested pH≥6.2 in at least 90% of units tested . Leukocyte-reduced Apheresis Platelets: At least 3.0 x 1011 platelets in 90% of units tested < 5.0 x 106 WBCs 95% of units tested pH≥6.2 in at least 90% of units tested Methods o Filter: “Fourth-generation” filters remove 99.99% WBCs o Apheresis methods: most apheresis machines have built-in leukoreduction mechanisms o Less efficient methods of reducing WBC content . Washing, deglycerolizing after thawing a frozen unit, centrifugation . These methods do not meet requirement of < 5.0 x 106 WBCs per unit of RBCs/apheresis platelets. Types of leukofiltration/leukoreduction o “Pre-storage” . Done within 24 hours of collection . May use inline filters at time of collection (apheresis) or post collection o “Pre-transfusion” leukoreduction/bedside leukoreduction . Done prior to transfusion . “Bedside” leukoreduction uses gravity-based filters at time of transfusion. Least desirable given variability in practice and absence of proficiency . Alternatively performed by transfusion service prior to issuing Benefits of leukoreduction o Prevention of alloimmunization to donor HLA antigens . Anti-HLA can mediate graft rejection and immune mediated destruction of platelets o Leukoreduced products are indicated for transplant recipients or patients who are likely platelet transfusion dependent o Prevention of febrile non-hemolytic transfusion reactions (FNHTR) .
    [Show full text]
  • Patient Information Leaflet – Plasma Exchange Procedure
    Therapeutic Apheresis Services Patient Information Leaflet – Plasma Exchange Procedure Introduction Antibodies, which normally help to protect you from infection, can begin to attack your own This leaflet has been written to give patients healthy cells, or an over production of proteins can information about plasma exchange (sometimes cause your blood to become thicker and slow down called plasmapheresis). If you would like any more the blood flow throughout your body. A plasma information or have any questions, please ask the exchange can help improve your symptoms, doctors and nurses involved in your treatment at although this may not happen immediately. the NHS Blood and Transplant (NHSBT) Therapeutic Apheresis Services Unit. Although plasma exchange may help with symptoms, it will not normally cure your condition When you have considered the information given as it does not switch off the production of the in this leaflet, and after we have discussed the harmful antibodies or proteins. It is likely that procedure and its possible risks with you, we will this procedure will form only one part of your ask you to sign a consent form to indicate that you treatment. are happy for the procedure to go ahead. Before any further procedures we will again check that you are happy to proceed. How do we perform Plasma Exchange? What is a plasma exchange? Plasma exchange is performed using a machine Blood is made up of red cells, white cells and called a Blood Cell Separator which can separate platelets which are carried around in fluid called blood into its various parts. The machine separates plasma.
    [Show full text]
  • Red Blood Cells, Leukocyte Reduced Covenant and AHS Sites
    This document applies to all Red Blood Cells, Leukocyte Reduced Covenant and AHS sites. Class: Human blood component, derived from OTHER NAMES: Packed red blood cells, Packed whole blood cells INTRAVENOUS OTHER ROUTES DIRECT IV Intermittent Continuous Infusion Infusion SC IM OTHER Acceptable No Yes No No No No Routes* * Professionals performing these restricted activities have received authorization from their regulatory college and have the knowledge and skill to perform the skill competently. DESCRIPTION OF PRODUCT: Red Blood Cell (RBC) concentrates are prepared from approximately 480mL whole blood usually collected in 70mL of anticoagulant. The unit is plasma reduced by centrifugation, platelet reduced by either centrifugation or filtration and leukocyte reduced by filtration. RBCs are typically resuspended in approximately 110mL of nutrient. Collected from volunteer donors by the Canadian Blood Services (CBS). Donor is screened and blood is tested for: i. Hepatitis B Surface Antigen (HBsAg) ii. Syphilis iii. Antibodies to Hepatitis B core antigen (HBcore), Hepatitis C Virus (HCV), Human T-cell Lymphotropic Virus (HTLV-1 and 2), Human Immune Deficiency Virus (HIV-1 and 2) iv. Nucleic Acid Testing (NAT) for presence of HCV RNA, HIV-1 RNA and West Nile Virus (WNV) RNA . CBS also tests blood for ABO/Rh and clinically significant antibodies. Some donors are tested for CMV status. RBCs do NOT contain any coagulation factors or platelets. AVAILABILITY: . Contact your local transfusion service/laboratory for ABO and Rh types stocked at your site. ABO compatible (not always identical) may be required if the transfusion service cannot provide sufficient quantities of the patient’s blood group (See ABO compatibility chart at: http://www.albertahealthservices.ca/assets/wf/lab/wf-lab-clin-tm-abo-compatability.pdf).
    [Show full text]